Cofrogliptin vs Prusogliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Cofrogliptin
Marketed by Haisco Pharmaceutical Group
NCT04556851 · Phase 3 · completed
This randomized, double-blind, placebo-controlled trial enrolled 476 patients and measured change in HbA1c, a standard efficacy measure in diabetes, at 24 weeks. Both HSK7653 doses lowered HbA1c significantly more than placebo (p<0.0001), meeting the trial's primary goal.
Next expected readout: June 2027 · NCT07122102 (registry estimate)
Reported efficacy
HbA1c Change From Baseline at Week 24 (Baseline and week 24): HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin (met)
Result source: NCT04564872
Prusogliptin · Shanzeping
Marketed by CSPC Pharmaceutical Group and partners
NCT04161430 · Phase 3 · completed
In this randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial, 766 patients with type 2 diabetes were randomized to DBPR108, sitagliptin, or placebo. DBPR108 reduced HbA1c significantly more than placebo at 24 weeks, with a treatment difference whose confidence interval excluded no effect.
Reported efficacy
Change from baseline in HbA1c (%) compared to placebo comparator at week 24 (Baseline, week 24): HbA1c change from baseline at week 24: -0.63% (DBPR108) vs -0.02% (placebo); treatment difference -0.61 percentage points (95% CI -0.77% to -0.44%). DBPR108 was superior to placebo. (met)
Result source: NCT04161430
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cofrogliptin | Prusogliptin |
|---|---|---|
| HbA1c, change | -1.0% vs -1.1%avs linagliptin 5 mgNCT045648721 other result
| -0.6% vs -0.0%a−0.6 vs placeboNCT041614301 other result
|
| Body weight, change (kg) | —Not posted · NCT04564872 | —Not posted · NCT04218734 |
| HbA1c below 7% | —Not posted · NCT04564872 | —Not posted · NCT04218734 |
| Fasting plasma glucose, change | —Not posted · NCT04564872 | —Not posted · NCT04218734 |
| 3-point MACE (% with event) | —Not posted · NCT04564872 | —Not posted · NCT04218734 |
HbA1c, change
- Cofrogliptin
- -1.0% vs -1.1%avs linagliptin 5 mgNCT04564872
1 other result
- -1.0% vs -1.1% NCT04564872
- Prusogliptin
- -0.6% vs -0.0%a−0.6 vs placeboNCT04161430
1 other result
- -0.7% vs -0.1% NCT04218734
Body weight, change (kg)
- Cofrogliptin
- —Not posted · NCT04564872
- Prusogliptin
- —Not posted · NCT04218734
HbA1c below 7%
- Cofrogliptin
- —Not posted · NCT04564872
- Prusogliptin
- —Not posted · NCT04218734
Fasting plasma glucose, change
- Cofrogliptin
- —Not posted · NCT04564872
- Prusogliptin
- —Not posted · NCT04218734
3-point MACE (% with event)
- Cofrogliptin
- —Not posted · NCT04564872
- Prusogliptin
- —Not posted · NCT04218734
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Cofrogliptin: 0 of 4 rows · Prusogliptin: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cofrogliptin | Prusogliptin |
|---|---|---|
| Dropout rate | — | 0%600 mga NCT01650324 · Phase 1 · registry result, not featured evidence show 3 more results0%300 mg NCT01650324 · Phase 1 · registry result, not featured evidence 0%100 mg NCT01650324 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01650324 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | — | —600 mga NCT01650324 · Phase 1 · registry result, not featured evidence show 3 more results—300 mg NCT01650324 · Phase 1 · registry result, not featured evidence —100 mg NCT01650324 · Phase 1 · registry result, not featured evidence —25 mg NCT01650324 · Phase 1 · registry result, not featured evidence |
| Serious AEs | — | 0%600 mga NCT01650324 · Phase 1 · registry result, not featured evidence show 3 more results0%300 mg NCT01650324 · Phase 1 · registry result, not featured evidence 0%100 mg NCT01650324 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01650324 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | — | 600 mga haematuria 16.7% (placebo 0%) infection 16.7% (placebo 0%) ligament sprain 16.7% (placebo 0%) NCT01650324 · Phase 1 · registry result, not featured evidence show 3 more results300 mg platelet count decreased 16.7% (placebo 0%) haematuria 0% (placebo 0%) infection 0% (placebo 0%) NCT01650324 · Phase 1 · registry result, not featured evidence 100 mg haematuria 0% (placebo 0%) infection 0% (placebo 0%) ligament sprain 0% (placebo 0%) NCT01650324 · Phase 1 · registry result, not featured evidence 25 mg haematuria 0% (placebo 0%) infection 0% (placebo 0%) ligament sprain 0% (placebo 0%) NCT01650324 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cofrogliptin
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cofrogliptin's landscape · Prusogliptin's landscape